• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

子宫肉瘤的治疗管理和预后指标:单机构真实世界数据。

Management of uterine sarcomas and prognostic indicators: real world data from a single-institution.

机构信息

Department of Clinical Therapeutics, Oncology Unit, Alexandra Hospital, Vasilisis Sofias, 80, Athens, Greece.

Obstetrics and Gynecology Department, Alexandra Hospital, Vasilisis Sofias, 80, Athens, Greece.

出版信息

BMC Cancer. 2018 Dec 13;18(1):1247. doi: 10.1186/s12885-018-5156-1.

DOI:10.1186/s12885-018-5156-1
PMID:30541504
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6292121/
Abstract

BACKGROUND

Uterine sarcomas consist a heterogeneous group of mesenchymal gynecological malignancies with unclear therapeutic recommendations and unspecific but poor prognosis, since they usually metastasize and tend to recur very often, even in early stages.

METHODS

We retrospectively analyzed all female patients with uterine sarcomas treated in our institution over the last 17 years. Clinico-pathological data, treatments and outcomes were recorded. Kaplan-Meier curves were plotted and time-to-event analyses were estimated using Cox regression.

RESULTS

Data were retrieved from 61 women with a median age of 53 (range: 27-78) years, at diagnosis. Fifty-one patients were diagnosed with leiomyosarcoma (LMS), 3 with high grade endometrial stromal sarcoma (ESS), 5 with undifferentiated uterine sarcoma (UUS), 1 with Ewing sarcoma (ES) and 1 with Rhabdomyosarcoma (RS). 24 cases had stage I, 7 stage II, 14 stage III and 16 stage IV disease. Median disease-free survival (DFS) in adjuvant approach was 18.83 months, and median overall survival (OS) 31.07 months. High mitotic count (> 15 mitoses) was significantly associated with worse OS (P < 0.001) and worse DFS (P = 0.028).

CONCLUSIONS

Mitotic count appears to be independent prognostic factor while further insights are needed to improve adjuvant and palliative treatment of uterine sarcomas.

摘要

背景

子宫肉瘤是一组异质性的间充质妇科恶性肿瘤,治疗建议不明确,预后通常较差,因为它们通常会转移,并且经常复发,即使在早期也是如此。

方法

我们回顾性分析了过去 17 年在我们机构治疗的所有女性子宫肉瘤患者。记录了临床病理数据、治疗方法和结果。绘制 Kaplan-Meier 曲线,并使用 Cox 回归估计时间事件分析。

结果

数据来自 61 名中位年龄为 53 岁(范围:27-78 岁)的女性患者,诊断时。51 例患者被诊断为平滑肌肉瘤(LMS),3 例为高级别子宫内膜间质肉瘤(ESS),5 例为未分化子宫肉瘤(UUS),1 例为尤文肉瘤(ES)和 1 例横纹肌肉瘤(RS)。24 例为 I 期,7 例为 II 期,14 例为 III 期,16 例为 IV 期。辅助治疗的中位无病生存(DFS)为 18.83 个月,中位总生存(OS)为 31.07 个月。高有丝分裂计数(>15 个有丝分裂)与 OS(P<0.001)和 DFS(P=0.028)较差显著相关。

结论

有丝分裂计数似乎是一个独立的预后因素,需要进一步深入了解以改善子宫肉瘤的辅助和姑息治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d03/6292121/9e88249a7212/12885_2018_5156_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d03/6292121/9e88249a7212/12885_2018_5156_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d03/6292121/9e88249a7212/12885_2018_5156_Fig1_HTML.jpg

相似文献

1
Management of uterine sarcomas and prognostic indicators: real world data from a single-institution.子宫肉瘤的治疗管理和预后指标:单机构真实世界数据。
BMC Cancer. 2018 Dec 13;18(1):1247. doi: 10.1186/s12885-018-5156-1.
2
Prognostic factors, oncological treatment and outcomes of uterine sarcoma: 10 years' clinical experience from a tertiary care center in Pakistan.巴基斯坦一家三级护理中心 10 年的临床经验:子宫肉瘤的预后因素、肿瘤治疗和结果。
BMC Cancer. 2023 Jun 5;23(1):510. doi: 10.1186/s12885-023-11000-3.
3
Clinical characteristics and prognosis analysis of uterine sarcoma: a single-institution retrospective study.子宫肉瘤的临床特征和预后分析:单中心回顾性研究。
BMC Cancer. 2022 Oct 7;22(1):1050. doi: 10.1186/s12885-022-10129-x.
4
Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma.157例子宫肉瘤的临床病理预后因素分析及软组织肉瘤验证分级评分的评估
Cancer. 2000 Mar 15;88(6):1425-31.
5
Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor.子宫肉瘤和恶性苗勒管混合瘤的结局与预后
Arch Gynecol Obstet. 2016 Aug;294(2):343-51. doi: 10.1007/s00404-015-3993-6. Epub 2015 Dec 28.
6
Survival outcomes and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma.子宫内膜间质肉瘤和未分化子宫肉瘤的生存结果和预后因素。
Clin Transl Oncol. 2021 Jun;23(6):1210-1219. doi: 10.1007/s12094-020-02512-6. Epub 2020 Nov 18.
7
Prognostic factors associated with uterine sarcomas: the experience of a single institution.子宫肉瘤的预后因素:单机构经验
J Obstet Gynaecol. 2019 Feb;39(2):231-236. doi: 10.1080/01443615.2018.1492529. Epub 2018 Oct 24.
8
Clinicopathological characteristics and prognosis of uterine sarcoma: a 10-year retrospective single-center study in China.中国 10 年回顾性单中心研究:子宫肉瘤的临床病理特征与预后。
Diagn Pathol. 2024 Jul 5;19(1):94. doi: 10.1186/s13000-024-01517-x.
9
Clinical characteristics and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma confirmed by central pathologic review: A multi-institutional retrospective study from the Japanese Clinical Oncology Group.中心病理复审证实的子宫内膜间质肉瘤和未分化子宫肉瘤的临床特征和预后因素:日本临床肿瘤学组的多机构回顾性研究。
Gynecol Oncol. 2023 Sep;176:82-89. doi: 10.1016/j.ygyno.2023.07.002. Epub 2023 Jul 19.
10
Stages I to II WHO 2003-defined low-grade endometrial stromal sarcoma: how much primary therapy is needed and how little is enough?世界卫生组织 2003 年定义的 I 期至 II 期低级别子宫内膜间质肉瘤:需要多少初始治疗,多少又足够?
Int J Gynecol Cancer. 2013 Mar;23(3):488-93. doi: 10.1097/IGC.0b013e318247aa14.

引用本文的文献

1
Survival guided adaptive clustering enhances mortality risk stratification and radiotherapy guidance in early stage uterine sarcoma.生存引导的适应性聚类可增强早期子宫肉瘤的死亡风险分层和放疗指导。
Sci Rep. 2025 Jul 25;15(1):27055. doi: 10.1038/s41598-025-13139-4.
2
Retrospective Analysis of -Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors.聚(ADP-核糖)聚合酶抑制剂治疗α改变子宫肉瘤的回顾性分析
JCO Precis Oncol. 2025 Mar;9:e2400765. doi: 10.1200/PO-24-00765. Epub 2025 Mar 21.
3
Survival Trends for Uterine Sarcomas from a Tertiary Center: The Oxford Experience.

本文引用的文献

1
ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity.ZC3H7B-BCOR 高级别子宫内膜间质肉瘤:一种新定义实体的 17 例报告。
Mod Pathol. 2018 Apr;31(4):674-684. doi: 10.1038/modpathol.2017.162. Epub 2017 Dec 1.
2
Uterine sarcoma - current perspectives.子宫肉瘤——当前观点
Int J Womens Health. 2017 Aug 31;9:597-606. doi: 10.2147/IJWH.S117754. eCollection 2017.
3
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
来自三级医疗中心的子宫肉瘤生存趋势:牛津经验
Diseases. 2024 Sep 2;12(9):200. doi: 10.3390/diseases12090200.
4
Prognostic Factors for Uterine Sarcoma and Carcinosarcoma: Insights from a 10-Year Follow-Up Study.子宫肉瘤和癌肉瘤的预后因素:一项 10 年随访研究的结果。
Med Sci Monit. 2023 Dec 7;29:e941562. doi: 10.12659/MSM.941562.
5
Accidental Morcellation of Uterine Leiomyosarcoma Influences Relapse Free Survival but Does Not Negatively Influence Overall Survival.子宫平滑肌肉瘤的意外粉碎术影响无复发生存率,但对总生存率无负面影响。
J Clin Med. 2023 Jan 11;12(2):591. doi: 10.3390/jcm12020591.
6
Clinical characteristics and prognosis analysis of uterine sarcoma: a single-institution retrospective study.子宫肉瘤的临床特征和预后分析:单中心回顾性研究。
BMC Cancer. 2022 Oct 7;22(1):1050. doi: 10.1186/s12885-022-10129-x.
7
Fertility-Sparing Management May Be Considered in Young Women with Uterine Sarcoma.子宫肉瘤的年轻女性可考虑保留生育功能的管理。
J Clin Med. 2022 Aug 15;11(16):4761. doi: 10.3390/jcm11164761.
8
Development and validation of tumor-size-stratified prognostic nomograms for patients with uterine sarcoma: A SEER database analysis.基于 SEER 数据库的肿瘤大小分层预后列线图模型的建立及其对子宫肉瘤患者的预后预测价值
Cancer Med. 2023 Jan;12(2):1339-1349. doi: 10.1002/cam4.5014. Epub 2022 Jul 16.
9
Prognostic factors and survival of patients with uterine sarcoma: a German unicenter analysis.子宫肉瘤患者的预后因素和生存情况:德国单中心分析。
Arch Gynecol Obstet. 2023 Mar;307(3):927-935. doi: 10.1007/s00404-022-06515-2. Epub 2022 Jul 3.
10
Retrospective Analysis of Patients with Gynaecological Uterine Sarcomas in a Tertiary Hospital.三级医院妇科子宫肉瘤患者的回顾性分析
J Pers Med. 2022 Feb 6;12(2):222. doi: 10.3390/jpm12020222.
吉西他滨与多西他赛对比阿霉素作为既往未治疗的晚期不可切除或转移性软组织肉瘤一线治疗的疗效(GeDDiS):一项随机对照3期试验
Lancet Oncol. 2017 Oct;18(10):1397-1410. doi: 10.1016/S1470-2045(17)30622-8. Epub 2017 Sep 4.
4
Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: Trends and survival outcomes.I期子宫平滑肌肉瘤的吉西他滨-多西他赛辅助化疗:趋势与生存结果
Gynecol Oncol. 2017 Oct;147(1):11-17. doi: 10.1016/j.ygyno.2017.07.122. Epub 2017 Jul 24.
5
Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas.有丝分裂指数截断值作为未分化子宫肉瘤预后标志物的验证。
Am J Surg Pathol. 2017 Sep;41(9):1231-1237. doi: 10.1097/PAS.0000000000000894.
6
Recent Developments in Surgical Pathology of the Uterine Corpus.子宫体外科病理学的最新进展
Arch Pathol Lab Med. 2017 Apr;141(4):528-541. doi: 10.5858/arpa.2016-0284-SA. Epub 2017 Feb 28.
7
Molecular characteristics of uterine sarcomas.子宫肉瘤的分子特征
Expert Rev Mol Diagn. 2017 May;17(5):515-522. doi: 10.1080/14737159.2017.1311790. Epub 2017 Apr 3.
8
Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome.子宫平滑肌肉瘤:分子生物学、临床管理和预后方面的最新进展综述。
BJOG. 2017 Jun;124(7):1028-1037. doi: 10.1111/1471-0528.14579. Epub 2017 Apr 1.
9
Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.短疗程、高剂量辅助化疗治疗高危成人软组织肉瘤:意大利肉瘤研究组和西班牙肉瘤研究组的一项随机临床试验的长期随访结果。
Ann Oncol. 2016 Dec;27(12):2283-2288. doi: 10.1093/annonc/mdw430. Epub 2016 Oct 11.
10
Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis.早期子宫平滑肌肉瘤辅助化疗的疗效:一项系统评价和荟萃分析。
Gynecol Oncol. 2016 Nov;143(2):443-447. doi: 10.1016/j.ygyno.2016.07.110. Epub 2016 Jul 29.